Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ointment shows promise for stubborn hand eczema

NCT ID NCT02664805

Symptom relief Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2a trial tested whether a new ointment called LEO 124249 can improve chronic hand eczema when applied twice daily for up to 8 weeks. 91 adults with hand eczema that didn't respond well to steroid creams took part. The study compared the active ointment to an inactive vehicle to see if it reduces redness, scaling, and itching.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LEO 124249 ointment
What this could lead to
If it works, this could point toward a new topical treatment option for chronic hand eczema that is not adequately controlled by steroids.
What could go wrong
This is an early proof-of-concept trial with only 91 participants, so results may not apply to everyone. The ointment may not prove more effective than the vehicle (inactive base).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

91 people

The number who actually took part.

Start date

Feb 2016

Finished

Oct 2016

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical diagnosis of chronic hand eczema with or without atopic etiology/background with a history of not adequately controlled disease activity with cutaneously applied steroid * Physician's Global Assessment of disease severity graded as at least mild at Visit 1 * In overall good health including well controlled diseases Exclusion Criteria: * Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), retinoids (e.g. alitretinoin) or corticosteroids within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used). * PUVA (Psoralen Ultraviolet A) or UVB (Ultraviolet B) therapy on the hands within 4 weeks prior to randomization * Cutaneously applied treatment with immunomodulators (pimecrolimus, tacrolimus) or corticosteroids on the hands within 2 weeks prior to randomization. * Use of systemic antibiotics or cutaneously applied antibiotics on the hands within 2 weeks prior to randomization * Concurrent skin diseases on the hands * Current diagnosis of exfoliative dermatitis * Significant clinical infection (impetiginized hand eczema) on the hands which requires antibiotic treatment * A marked abnormal ECG at baseline * Known hepatic dysfunction or hepatic dysfunction tested at Screening * Current participation in any other interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hand eczema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hand eczema

Contacts and locations

Locations

  • Allergie-Centrum-Charité Klinik für Dermatologie, Venerologie und Allergologie

    Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.